Werewolf Therapeutics, Inc. (HOWL)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why
Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Werewolf Therapeutics stock exploded higher and what comes next?
Werewolf Therapeutics (HOWL) stock exploded higher on Friday morning after management said the company has agreed to a definitive all-stock merger with Ambros Therapeutics. The combined company will pivot to focus on Ambros' Phase 3 drug candidate – neridronate – for Complex Regional Pain Syndrome Type 1 (CRPS-1), backed by an oversubscribed $150 million private placement from top-tier institutional investors like RA Capital and Janus Henderson.
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline
Werewolf Therapeutics (HOWL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates
Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.14 per share a year ago.
